Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0HTHLN
ADC Name
CN119365219A+ADC
Synonyms
CN119365219A+ADC
   Click to Show/Hide
Organization
ABBVIE BIOTHERAPEUTICS INC.
Drug Status
Investigative
Drug-to-Antibody Ratio
2-8
Structure
Antibody Name
undisclosed
Antigen Name
B-lymphocyte antigen CD19 (CD19)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
Mc-Gly-Gly-Phe-Gly
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
0.544
nM
CVCL_0093
Adult B acute lymphoblastic leukemia
Half Maximal Effective Concentration (EC50) 
0.928
nM
CVCL_0103
B-lymphoblastic leukemia
Half Maximal Effective Concentration (EC50) 
0.939
nM
CVCL_0511
EBV-related Burkitt lymphoma
Half Maximal Effective Concentration (EC50) 
1.061
nM
CVCL_1878
Diffuse large B-cell lymphoma germinal center B-cell type, Diffuse large B-cell lymphoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.544 nM Positive CD19 expression (CD19+++/++)
Method Description
Flow cytometry was used to evaluate the cell surface binding of ADC-1 to different cancer cell lines expressing CD19 endogenously and 293T cells transduced with full-length human CD19.
In Vitro Model Adult B acute lymphoblastic leukemia RS4;11 cells CVCL_0093
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.928 nM Positive CD19 expression (CD19+++/++)
Method Description
Flow cytometry was used to evaluate the cell surface binding of ADC-1 to different cancer cell lines expressing CD19 endogenously and 293T cells transduced with full-length human CD19.
In Vitro Model B-lymphoblastic leukemia SUP-B15 cells CVCL_0103
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 0.939 nM Positive CD19 expression (CD19+++/++)
Method Description
Flow cytometry was used to evaluate the cell surface binding of ADC-1 to different cancer cell lines expressing CD19 endogenously and 293T cells transduced with full-length human CD19.
In Vitro Model EBV-related Burkitt lymphoma Raji cells CVCL_0511
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 1.061 nM Positive CD19 expression (CD19+++/++)
Method Description
Flow cytometry was used to evaluate the cell surface binding of ADC-1 to different cancer cell lines expressing CD19 endogenously and 293T cells transduced with full-length human CD19.
In Vitro Model Diffuse large B-cell lymphoma germinal center B-cell type, Diffuse large B-cell lymphoma OCI-LY19 cells CVCL_1878
References
Ref 1 Anti-CD19 antibody-drug conjugates